account_id none on file
legal_name Neuphoria Therapeutics Inc.
ticker NEUP
cik 1191070
domain neuphoriatx.com
linkedin_company_url https://www.linkedin.com/company/neuphoriatx
entry_point_account_id none on file
exchange Nasdaq
hq Burlington, MA, United States
calls 0 filings 3 executives 0 family 0
why_nownone on file
callsnone on file
filings
• expenses incurred under agreements with outside consultants and advisors, including their fees and related travel expenses; and
filing / May 15, 2026 / receipt
As part of the restructuring initiative, the Company incurred employee termination costs of approximately $1.4 million, and other restructuring costs of approximately $0.4 million, inclusive of impairment of the right-of-use asset, partially offset by refundable credits on contract terminations of approximately $0.6 million.
filing / May 15, 2026 / receipt
As a result, we may be forced to further reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings including, but not limited to, for the possibility of continuing our PTSD clinical trial program or other working capital needs.
filing / May 15, 2026 / receipt
executivesnone on file
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug neuphoria-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$